SCHEMBL10053286

SCHEMBL10053286

CN1CCCOB(c2cccc(Cl)c2)c2ccccc2C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 6/20 0.36
DRD5 P21918 5/20 0.36
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
HRH4 Q9H3N8 1/20 0.33
DRD2 P14416 4/20 0.33
DRD4 P21917 4/20 0.33
DRD3 P35462 4/20 0.33
PDE4B Q07343 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
SLC6A2 P23975 3/20 0.32
SLC6A3 Q01959 3/20 0.32
SLC6A4 P31645 2/20 0.32
HTR2A P28223 2/20 0.32
HTR2C P28335 2/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
RAB9A P51151 1/20 0.32
CHRM2 P08172 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL596553 0.81 CA12 (0.37) PDE4BHTR2CSMN1; SMN2
SCHEMBL14390488 0.79 CA12 (0.36) PDE4BSLC6A2SLC6A3NPC1ALDH1A1
SCHEMBL595037 0.78 CA1 (0.46) PDE4BMEN1KMT2AHTR2CNPC1
SCHEMBL10053211 0.78 CA1 (0.33)
SCHEMBL10053214 0.77 CA12 (0.37)
SCHEMBL10053288 0.77 PNMT (0.34) MAOBSLC6A4HTR2AHTR2CNPC1
SCHEMBL500424 0.75 CA1 (0.43) PDE4BHTR2CNPC1RAB9ASMN1; SMN2
SCHEMBL3457424 0.69 KMT2A (0.38) HRH4DRD2DRD3MEN1KMT2A
SCHEMBL10053284 0.65 CA1 (0.46) MEN1KMT2ANPC1ALDH1A1RAB9A
SCHEMBL6829118 0.64 ALDH1A1 (0.36) MEN1KMT2ASLC6A3SLC6A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106031-B2 Hydrolytically-resistant boron-containing therapeutics and methods of use ANACOR PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-8106031-B2 Hydrolytically-resistant boron-containing therapeutics and methods of use ANACOR PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
WO-2007131072-A2 HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE ANACOR PHARMACEUTICALS, INC. (US) 2007-11-15 WO disclosed
US-20070265226-A1 Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use ANACOR PHARMACEUTICALS (US) 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265226-A1 Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use GAA, BTD, MANBA DRD1 4850/4885DRD5 4825/4885MAOA 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.